Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 6/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4620158 | 0.87 | CAMKK1 (0.38) | EGFRERBB2HRH3 | |
| SCHEMBL2797310 | 0.84 | CAMKK1 (0.39) | EGFRERBB2NPC1RAB9AHRH3 | |
| SCHEMBL3520449 | 0.84 | EGFR (0.53) | EGFRERBB2 | |
| SCHEMBL2799360 | 0.83 | EGFR (0.39) | EGFRERBB2 | |
| SCHEMBL5735308 | 0.83 | SPHK2 (0.43) | SPHK2CHRNB2CHRNA7CHRNA4CHRNA5 | |
| SCHEMBL3520472 | 0.83 | SPHK2 (0.43) | SPHK2CHRNB2CHRNA7CHRNA4CHRNA5 | |
| SCHEMBL3429735 | 0.80 | CHRNB2 (0.38) | SPHK2CHRNB2CHRNA7CHRNA4CHRNA5 | |
| SCHEMBL5315779 | 0.77 | CHRNB2 (0.58) | SPHK2CHRNB2CHRNA7CHRNA4CHRNA5 | |
| SCHEMBL5132712 | 0.77 | CHRNB2 (0.58) | SPHK2CHRNB2CHRNA7CHRNA4CHRNA5 | |
| SCHEMBL3827589 | 0.76 | SPHK2 (0.66) | SPHK2CHRNB2CHRNA7CHRNA4CHRNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659279-B2 | 2-{(2S)-2-[({4-[3-Chloro-4-fluoroanilino]-7-methoxyquinazolin-5-yl}oxy)methyl]pyrrolidin-1-yl}-2-oxoethanol; epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors; breast, colorectal and head and neck cancer | ASTRAZENECA AB (SE) | 2010-02-09 | — | — | US | disclosed |
| EP-1622620-B1 | QUINAZOLINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| US-20060211714-A1 | Quinazoline derivatives and their use in the treatment of cancer | ASTRAZENECA AB (SE) | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211714-A1 | Quinazoline derivatives and their use in the treatment of cancer | EGFR, ERBB2, ERBB4 | SPHK2 3156/4885EGFR 1/4885ERBB2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.